Table of contents


Top

Editorial

Join the dots p837

doi:10.1038/nbt0808-837

Pushing biotech as the 'solution' to the world's problems is doing more harm than good.


Top

News

EGFR inhibitors embrace KRAS pp839 - 840

Cormac Sheridan

doi:10.1038/nbt0808-839


GSK slashes internal R&D p840

Nuala Moran

doi:10.1038/nbt0808-840


Myriad stumbles, Wyeth closes on Alzheimer's pp841 - 843

Randy Osborne

doi:10.1038/nbt0808-841


FDA and surrogate endpoints in Alzheimer's disease p843

Randy Osborne

doi:10.1038/nbt0808-843


Infections cast cloud over Novartis' MS therapy pp844 - 845

Ken Garber

doi:10.1038/nbt0808-844


India harmonizes regulations p845

K S Jayaraman

doi:10.1038/nbt0808-845a


FDA probes TNF blockers p845

Brady Huggett

doi:10.1038/nbt0808-845b


GSK bird flu vaccine p846

Susan Aldridge

doi:10.1038/nbt0808-846a


Cabilly patent finale p846

Emily Waltz

doi:10.1038/nbt0808-846b


UK strong arms industry over drug pricing pp846 - 847

Peter Mitchell

doi:10.1038/nbt0808-846c


Pharma to boycott UK? p847

Peter Mitchell

doi:10.1038/nbt0808-847a


EC/FDA joint inspections p847

Barbara Nasto

doi:10.1038/nbt0808-847b


Supply size matters p847

Susan Aldridge

doi:10.1038/nbt0808-847c


Profile: Olivier Rabin p849

Henry Nicholls

doi:10.1038/nbt0808-849

With Beijing 2008 in full swing, the World Anti-Doping Agency's Olivier Rabin is looking for help from the biotech and pharma industry in the battle against cheaters.


Data Page

Q2 finance fall-off p850

Stacy Lawrence

doi:10.1038/nbt0808-850


News Feature

Do biomaterials really mean business? pp851 - 853

Emily Waltz

doi:10.1038/nbt0808-851

Receiving only a fraction of the investment set aside for biofuels, biomaterials will likely have to piggyback on technological advances in energy production to compete with petroleum-based products in the marketplace. Emily Waltz reports.


Top

Bioentrepreneur

Building a business

The economics of licensing contracts pp855 - 857

Richard Mason, Nicos Savva & Stefan Scholtes

doi:10.1038/bioe.2008.7


Top

Opinion and Comment

Correspondence

GMO testing—trade, labeling or safety first? pp858 - 859

Arne Holst-Jensen

doi:10.1038/nbt0808-858


First evaluation of the European hESCreg pp859 - 860

Joeri Borstlap, Glyn Stacey, Andreas Kurtz, Anja Elstner, Alexander Damaschun, Begoña Arán & Anna Veiga

doi:10.1038/nbt0808-859


Guidelines for reporting the use of mass spectrometry in proteomics pp860 - 861

Chris F Taylor, Pierre-Alain Binz, Ruedi Aebersold, Michel Affolter, Robert Barkovich, Eric W Deutsch, David M Horn, Andreas Hühmer, Martin Kussmann, Kathryn Lilley, Marcus Macht, Matthias Mann, Dieter Müller, Thomas A Neubert, Janice Nickson, Scott D Patterson, Roberto Raso, Kathryn Resing, Sean L Seymour, Akira Tsugita, Ioannis Xenarios, Rong Zeng & Randall K Julian, Jr

doi:10.1038/nbt0808-860


Guidelines for reporting the use of mass spectrometry informatics in proteomics p862

Pierre-Alain Binz, Robert Barkovich, Ronald C Beavis, David Creasy, David M Horn, Randall K Julian, Jr, Sean L Seymour, Chris F Taylor & Yves Vandenbrouck

doi:10.1038/nbt0808-862


Guidelines for reporting the use of gel electrophoresis in proteomics pp863 - 864

Frank Gibson, Leigh Anderson, Gyorgy Babnigg, Mark Baker, Matthias Berth, Pierre-Alain Binz, Andy Borthwick, Phil Cash, Billy W Day, David B Friedman, Donita Garland, Howard B Gutstein, Christine Hoogland, Neil A Jones, Alamgir Khan, Joachim Klose, Angus I Lamond, Peter F Lemkin, Kathryn S Lilley, Jonathan Minden, Nicholas J Morris, Norman W Paton, Michael R Pisano, John E Prime, Thierry Rabilloud, David A Stead, Chris F Taylor, Hans Voshol, Anil Wipat & Andrew R Jones

doi:10.1038/nbt0808-863


The PSI-MOD community standard for representation of protein modification data pp864 - 866

Luisa Montecchi-Palazzi, Ron Beavis, Pierre-Alain Binz, Robert J Chalkley, John Cottrell, David Creasy, Jim Shofstahl, Sean L Seymour & John S Garavelli

doi:10.1038/nbt0808-864


Top

Features

Off-label or off-limits? pp867 - 875

Mark Ratner & Trisha Gura

doi:10.1038/nbt0808-867

Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.


Patents

The London Agreement and the future of parallel imports pp877 - 879

Justine Muir

doi:10.1038/nbt0808-877

Are European patents really getting cheaper, and if so, what effect will this have on parallel or so-called gray imports?


Recent patent applications in DNA synthesis p880

doi:10.1038/nbt0808-880


Top

News and Views

Sequencing sliced ends reveals microRNA targets pp881 - 882

Ian R Henderson & Steven E Jacobsen

doi:10.1038/nbt0808-881

Global sequencing of cleaved mRNAs enables identification of the targets of microRNA silencing.

See also: Research by German et al.


Nematology: terra incognita no more pp882 - 884

James P McCarter

doi:10.1038/nbt0808-882

The genome sequence of the plant-parasitic roundworm Meloidogyne incognita opens new avenues to boosting food production.

See also: Research by Abad et al.


Antibody-drug conjugates ace the tolerability test pp884 - 885

Nitin K Damle

doi:10.1038/nbt0808-884

Near-uniform, low-level conjugation of cytotoxins to antitumor antibodies increases their tolerability without compromising efficacy.

See also: Research by Junutula et al.


A welcome burst of human antibodies pp886 - 887

Michael B Zwick, Johannes S Gach & Dennis R Burton

doi:10.1038/nbt0808-886

A new method allows rapid identification of human monoclonal antibodies from immune or vaccinated individuals.


Research Highlights p888

doi:10.1038/nbt0808-888


Top

Computational Biology

Commentary

Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project pp889 - 896

Chris F Taylor, Dawn Field, Susanna-Assunta Sansone, Jan Aerts, Rolf Apweiler, Michael Ashburner, Catherine A Ball, Pierre-Alain Binz, Molly Bogue, Tim Booth, Alvis Brazma, Ryan R Brinkman, Adam Michael Clark, Eric W Deutsch, Oliver Fiehn, Jennifer Fostel, Peter Ghazal, Frank Gibson, Tanya Gray, Graeme Grimes, John M Hancock, Nigel W Hardy, Henning Hermjakob, Randall K Julian, Jr, Matthew Kane, Carsten Kettner, Christopher Kinsinger, Eugene Kolker, Martin Kuiper, Nicolas Le Novère, Jim Leebens-Mack, Suzanna E Lewis, Phillip Lord, Ann-Marie Mallon, Nishanth Marthandan, Hiroshi Masuya, Ruth McNally, Alexander Mehrle, Norman Morrison, Sandra Orchard, John Quackenbush, James M Reecy, Donald G Robertson, Philippe Rocca-Serra, Henry Rodriguez, Heiko Rosenfelder, Javier Santoyo-Lopez, Richard H Scheuermann, Daniel Schober, Barry Smith, Jason Snape, Christian J Stoeckert, Jr, Keith Tipton, Peter Sterk, Andreas Untergasser, Jo Vandesompele & Stefan Wiemann

doi:10.1038/nbt.1411

The Minimum Information for Biological and Biomedical Investigations (MIBBI) project aims to foster the coordinated development of minimum-information checklists and provide a resource for those exploring the range of extant checklists.


Primer

What is the expectation maximization algorithm? pp897 - 899

Chuong B Do & Serafim Batzoglou

doi:10.1038/nbt1406

The expectation maximization algorithm arises in many computational biology applications that involve probabilistic models. What is it good for, and how does it work?


Top

Research

Perspective

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment pp901 - 908

Jinhai Wang, Jay Lozier, Gibbes Johnson, Susan Kirshner, Daniela Verthelyi, Anne Pariser, Elizabeth Shores & Amy Rosenberg

doi:10.1038/nbt.1484


Articles

Genome sequence of the metazoan plant-parasitic nematode Meloidogyne incognita pp909 - 915

Pierre Abad, Jérôme Gouzy, Jean-Marc Aury, Philippe Castagnone-Sereno, Etienne G J Danchin, Emeline Deleury, Laetitia Perfus-Barbeoch, Véronique Anthouard, François Artiguenave, Vivian C Blok, Marie-Cécile Caillaud, Pedro M Coutinho, Corinne Dasilva, Francesca De Luca, Florence Deau, Magali Esquibet, Timothé Flutre, Jared V Goldstone, Noureddine Hamamouch, Tarek Hewezi, Olivier Jaillon, Claire Jubin, Paola Leonetti, Marc Magliano, Tom R Maier, Gabriel V Markov, Paul McVeigh, Graziano Pesole, Julie Poulain, Marc Robinson-Rechavi, Erika Sallet, Béatrice Ségurens, Delphine Steinbach, Tom Tytgat, Edgardo Ugarte, Cyril van Ghelder, Pasqua Veronico, Thomas J Baum, Mark Blaxter, Teresa Bleve-Zacheo, Eric L Davis, Jonathan J Ewbank, Bruno Favery, Eric Grenier, Bernard Henrissat, John T Jones, Vincent Laudet, Aaron G Maule, Hadi Quesneville, Marie-Noëlle Rosso, Thomas Schiex, Geert Smant, Jean Weissenbach & Patrick Wincker

doi:10.1038/nbt.1482

Biological control of the root-knot nematode Meloidogyne incognita, one of the world's most destructive crop pathogens, presents a major opportunity for safely improving global agricultural yields. Its 86-Mb genome—the first to be sequenced for a strictly parthenogenetic species—provides a blueprint to design new strategies for plant protection.

See also: News and Views by McCarter


A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types pp916 - 924

Marius Wernig, Christopher J Lengner, Jacob Hanna, Michael A Lodato, Eveline Steine, Ruth Foreman, Judith Staerk, Styliani Markoulaki & Rudolf Jaenisch

doi:10.1038/nbt1483

Generating induced pluripotent stem (iPS) cells is still an inefficient process, in part because the delivery of reprogramming factors by retroviral vectors yields cell populations that are genetically heterogeneous. Wernig et al. increase efficiency by producing iPS-cell chimeric mice from which they isolate cells bearing identical proviral insertions that support drug-inducible reprogramming.


Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index pp925 - 932

Jagath R Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D Leipold, Sylvia Weir, Yvonne Chen, Michelle Simpson, Siao Ping Tsai, Mark S Dennis, Yanmei Lu, Y Gloria Meng, Carl Ng, Jihong Yang, Chien C Lee, Eileen Duenas, Jeffrey Gorrell, Viswanatham Katta, Amy Kim, Kevin McDorman, Kelly Flagella, Rayna Venook, Sarajane Ross, Susan D Spencer, Wai Lee Wong, Henry B Lowman, Richard Vandlen, Mark X Sliwkowski, Richard H Scheller, Paul Polakis & William Mallet

doi:10.1038/nbt.1480

Systemic toxicity associated with heterogeneity in the stoichiometries and sites of drug attachment is a major hurdle to developing antibody-drug conjugates (ADCs) for cancer therapy. Junutula et al. engineer cysteine residues in constant domains to produce near-homogenous ADCs that are better tolerated than conventional ADCs, without any loss of antitumor activity.

See also: News and Views by Damle


A small molecule enhances RNA interference and promotes microRNA processing pp933 - 940

Ge Shan, Yujing Li, Junliang Zhang, Wendi Li, Keith E Szulwach, Ranhui Duan, Mohammad A Faghihi, Ahmad M Khalil, Lianghua Lu, Zain Paroo, Anthony W S Chan, Zhangjie Shi, Qinghua Liu, Claes Wahlestedt, Chuan He & Peng Jin

doi:10.1038/nbt.1481

Little is known about the regulation of RNA interference (RNAi). Shan et al. constructed a reporter system to monitor RNAi activity and identified a small molecule that increases RNAi by facilitating the interaction between small RNAs and a protein involved in small RNA loading and processing.


Letter

Global identification of microRNA–target RNA pairs by parallel analysis of RNA ends pp941 - 946

Marcelo A German, Manoj Pillay, Dong-Hoon Jeong, Amit Hetawal, Shujun Luo, Prakash Janardhanan, Vimal Kannan, Linda A Rymarquis, Kan Nobuta, Rana German, Emanuele De Paoli, Cheng Lu, Gary Schroth, Blake C Meyers & Pamela J Green

doi:10.1038/nbt1417

The targets of a microRNA (miRNA) are usually identified by computational analysis of sequences complementary to the miRNA. Working with inflorescence tissue of Arabidopsis, German et al. devise an experimental approach in which the products of miRNA-mediated cleavage are sequenced and used to identify miRNA–target RNA pairs.

See also: News and Views by Henderson & Jacobsen


Top

Errata

Erratum: HIV vaccine controversy p947

K S Jayaraman

doi:10.1038/nbt0808-947a


Erratum: Response to HIV vaccine trials in India p947

K S Jayaraman

doi:10.1038/nbt0808-947b


Erratum: Can 'double blockbuster' strengthen Amgen's backbone? p947

Cormac Sheridan

doi:10.1038/nbt0808-947c


Erratum: Biotech slumps in Q1 p947

Stacy Lawrence

doi:10.1038/nbt0808-947d


Top

Naturejobs

Careers and Recruitment

Westernizing Eastern-bloc science pp949 - 950

Quirin Schiermeier

doi:10.1038/nbt0808-949

Scientists in newer member countries are learning how to use what the European Union offers.


People

People p952

doi:10.1038/nbt0808-952


Top

Extra navigation

Open Innovation Challenges

naturejobs

ADVERTISEMENT